Additionally, it was reported that miR-5590-3p inhibited tumour growth in gastric cancer by targeting DDX5 [28], and repressed diffuse large B cell lymphoma progression and immune evasion through targeting ZEB1 to regulate PD-1/PD-L1 checkpoint [29]. Here, DDX5 is linked to neoplasm.